Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325748 · ClinicalTrials.gov registry record · Phase 1
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
A Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies, sponsored by Senti Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 8
- Study locations
NCT06325748: Active Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies, sponsored by Senti Biosciences.
NCT06325748 is a Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies that is active but no longer recruiting, run by Senti Biosciences. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06325748, a Phase 1 study of AML/MDS and CD33 Expressing Hematological Malignancies, is active but no longer recruiting, sponsored by Senti Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Primary Outcome
Incidence, type, frequency, and severity of adverse events and dose limiting toxicities will be assessed to determine the maximum tolerated dose and/or recommended phase 2 dose and dosing regimen
Conditions Studied
Interventions
- BIOLOGICAL SENTI-202
Study Locations (8)
Texas
- MD Anderson Cancer Center - Houston
- Methodist Healthcare - San Antonio
California
- UCLA Medical Center - Los Angeles
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic - Jacksonville
Tennessee
- TriStar Bone Marrow Transplant - Nashville
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Victoria
- Peter MacCallum Cancer Center - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2040-08 |
| Phase | Phase 1 |
What the registry record for NCT06325748 still lists
NCT06325748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with AML/MDS appearing as the primary indexed condition, and to 1 intervention - of which SENTI-202 is the first listed.
NCT06325748 lists 8 locations in 7 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06325748 about?
NCT06325748 is a clinical study titled "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS". This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
What is the current status of trial NCT06325748?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-04-22. Estimated completion is 2040-08.
What conditions does trial NCT06325748 study?
This clinical trial studies the following conditions: AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies.
What interventions are being tested in trial NCT06325748?
The interventions under investigation include: SENTI-202 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06325748?
This trial is sponsored by Senti Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06325748 being conducted?
This trial has 8 study locations across California, Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML/MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06325748's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI